Literature DB >> 10364320

Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.

R Merat1, H Raoul, T Leste-Lasserre, P Sonigo, G Pancino.   

Abstract

Lentiviruses have in their transmembrane glycoprotein (TM) a highly immunogenic structure referred to as the principal immunodominant domain (PID). The PID forms a loop of 5 to 7 amino acids between two conserved cysteines. Previous studies showed that envelope (Env) glycoprotein functions of feline immunodeficiency virus (FIV) could be retained after extensive mutation of the PID loop sequence, in spite of its high conservation. In order to compare Env function in different lentiviruses, either random mutations were introduced in the PID loop sequence of human immunodeficiency virus type 1 (HIV-1) or the entire HIV-1 PID loop was replaced by the corresponding PID loop of FIV or simian immunodeficiency virus (SIV). In the macrophage-tropic HIV-1 ADA Env, mutations impaired the processing of the gp160 Env precursor, thereby abolishing viral infectivity. However, 6 of the 108 random Env mutants that were screened retained the capacity to induce cell membrane fusion. The SIV and FIV sequences and five random mutations were then introduced in the context of T-cell-line-adapted HIV-1 LAI which, although phenotypically distant from HIV-1 ADA, has an identical PID loop sequence. In contrast to the situation for HIV-1 ADA mutants, the cleavage of the Env precursor was unaffected in most HIV-1 LAI mutants. Such mutations, however, resulted in increased shedding of the gp120 surface glycoprotein (SU) from the gp41 TM. The HIV-1 LAI Env mutants showed high fusogenic efficiency. Three Env mutants retained the capacity to mediate virus entry in target cells, although less efficiently than the wild-type Env, and allowed the reconstitution of infectious molecular clones. These results indicated that in HIV-1, like FIV, the conserved PID sequence can be changed without impairing Env function. However, functional constraints on the PID of HIV-1 vary depending on the structural context of Env, presumably in relation to the role of the PID in the interaction of the SU and TM subunits and the stability of the Env complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364320      PMCID: PMC112629     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?

Authors:  T F Schulz; B A Jameson; L Lopalco; A G Siccardi; R A Weiss; J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

2.  Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage.

Authors:  D Dedera; R L Gu; L Ratner
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.

Authors:  L A Cavacini; C L Emes; A V Wisnewski; J Power; G Lewis; D Montefiori; M R Posner
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-20       Impact factor: 2.205

4.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Authors:  M Groenink; R A Fouchier; S Broersen; C H Baker; M Koot; A B van't Wout; H G Huisman; F Miedema; M Tersmette; H Schuitemaker
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

5.  Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2.

Authors:  T Dragic; M Alizon
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.

Authors:  W J Syu; W R Lee; B Du; Q C Yu; M Essex; T H Lee
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.

Authors:  J Cao; L Bergeron; E Helseth; M Thali; H Repke; J Sodroski
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.

Authors:  G Pancino; C Chappey; W Saurin; P Sonigo
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.

Authors:  L Lopalco; R Longhi; F Ciccomascolo; A De Rossi; M Pelagi; F Andronico; J P Moore; T Schulz; A Beretta; A G Siccardi
Journal:  AIDS Res Hum Retroviruses       Date:  1993-01       Impact factor: 2.205

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  12 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160.

Authors:  Jayita Sen; Amy Jacobs; Haiqing Jiang; Lijun Rong; Michael Caffrey
Journal:  Protein Sci       Date:  2007-06       Impact factor: 6.725

3.  Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.

Authors:  A L Maerz; H E Drummer; K A Wilson; P Poumbourios
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.

Authors:  Florestan Desmaris; David Lemaire; Sylvie Ricard-Blum; Benoît Chatrenet; Eric Forest
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.

Authors:  B Labrosse; C Treboute; M Alizon
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl L Wiley; Linnea Schiffner; Bruce Travis; Shawn Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.

Authors:  L G Abrahamyan; R M Markosyan; J P Moore; F S Cohen; G B Melikyan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.

Authors:  Sally L Painter; Roman Biek; David C Holley; Mary Poss
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Annie David; Hugues Sudry; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 10.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.